The Zephyr valve is a one-way valve designed to reduce hyperinflation. The valve blocks airflow to the diseased region of the lung to allow the healthy region to expand and function more efficiently, resulting in improved breathing and quality of life.
During the 60-minute procedure, 3-5 Zephyr valves are placed in airways leading to the diseased region of the lung. The valves block air from entering the diseased region and allow trapped air and fluids to escape. The goal is to reduce the volume of the diseased region so that the healthy region can function more efficiently.
Zephyr valves have been clinically documented to improve patient outcomes. This may include significant improvements in lung function, exercise tolerance and quality of life metrics, as well as long-term survival benefits for severe emphysema patients. With over a decade of clinical experience, Zephyr valves significantly improve the lives of patients who undergo treatment.
As with any medical procedure, there are risks associated with the Zephyr valve and procedure. Risks include a temporary acute worsening of symptoms, pneumonia, increased mucus secretions, and wheezing. The risk of pneumothorax (air leak in the lung) is increased during the initial period post procedure. Your doctor will review these risks with you to help you understand them.
After the procedure, you may stay in hospital for 1-4 nights for observation.
The valves are designed to be permanent, however the valves can be easily removed if your doctor deems it medically necessary.
Zephyr valves may be a treatment option for you if you have severe emphysema. Your doctor will conduct certain tests to determine if you are a potential candidate for endoscopic lung volume reduction.
The Zephyr valve procedure is available in over 20 countries. Find a doctor
The Zephyr valve is not available in the United States. It is limited by United States law to investigational use.